Media Pack|Subscribe|E-Newsletter
|Admin
Biotechnology Media Insights Logo
ENTRegeneron

Regeneron and Sanofi Receive FDA Approval for Dupixent in Pediatric Chronic Rhinosinusitis with Nasal Polyps

BMI

Biotechnology Media Insights

Editorial Team · April 10, 2025

Regeneron and Sanofi announce FDA approval of Dupixent for adolescents aged 12 and older with chronic rhinosinusitis with nasal polyps.

Pharmaceutical research laboratory with drug development equipment

Regeneron and Sanofi today announced that the FDA has approved Dupixent (dupilumab) for adolescents aged 12 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). The approval was based on results from the Phase 3 LIBERTY NP SINUS-24 and SINUS-52 trials.

BMI

Biotechnology Media Insights

Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.

← Previous

Bristol Myers Squibb Reports Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis

Next →

Vertex Pharmaceuticals Reports Positive Phase 3 Results for Next-Generation Cystic Fibrosis Triple Combination

Biotechnology Media Insights — Pharma & Life Sciences News